Welcome and Introductions
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO
IMF Medical Advisor
(TGen, City of Hope—Phoenix, AZ)
Myeloma 101: What You Need to Know
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO
IMF Medical Advisor
(TGen, City of Hope—Phoenix, AZ)
Management for Newly Diagnosed, NOT Going to Transplant
Noffar Bar, MD
(Yale School of Medicine — New Haven, CT)
Q&A
Myeloma: Putting the Pieces of the Puzzle Together
Amy Pierre, MSN, RN, ANP-BC
IMF Nurse Leadership Board Member
(Memorial Sloan Kettering Cancer Center & Flatiron Health — New York, NY)
Q&A with Panel
Closing Remarks
Speakers
Noffar Bar, MD
Yale School of Medicine — New Haven, CT
Ciara Freeman, MD, PhD
Moffitt Cancer Center — Tampa, FL
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO
IMF Medical Advisor
Amy Pierre, MSN, RN, ANP-BC
IMF Nurse Leadership Board Member
Topics Covered in This Workshop:
Additional Resources:
Download the IMF's Multiple Myeloma Informational Booklets:
Download IMF publications
What Is a Clinical Trial?
*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:
- CANOVA Clinical Trial Fact Sheet
clinicaltrials.gov Identifier: NCT03539744 - Phase II Relapsed or Refractory Venetoclax Trial
clinicaltrials.gov Identifier: NCT02899052 - Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib
clinicaltrials.gov Identifier: NCT03314181
Workshop Sponsors:
With Support From: Abbvie, BMS, GSK, Johnson & Johnson, Karyopharm, Kite/Arcellx, Legend Biotech, and Pfizer
(The IMF is not responsible for content provided by the links below and you may be subject to the Privacy Policy and Terms & Conditions of the destination site(s).)
.png)
